Popular Articles

First Human Receives Cardiac Stem Cells In Clinical Trial To Heal Damage Caused By Heart Attacks
Doctors at the Cedars-Sinai Heart Institute announced today the completion of the first procedure in which a patient"s own heart tissue was used to grow specialized heart stem cells that were then injected back into the patient"s heart in an effort to repair and re-grow healthy muscle in a heart that had been injured by a heart attack.

In Mouse Study Immune Cells Ameliorate Hypertension-Induced Cardiac Damage
Researchers in Berlin, Germany have found that a specific type of immune cell, the regulatory T lymphocyte (Treg) plays an important role in hypertension-induced cardiac damage. The injected Treg that they harvested from donor mice into recipient mice were infused with angiotensin II, a blood pressure-raising peptide. The Tregs had no influence on the blood pressure response to angiotensin II. Nonetheless, cardiac enlargement, fibrosis, and inflammation was sharply reduced by Treg treatment. Furthermore, the tendency to develop abnormal heart rhythms that could lead to sudden cardiac death was also reduced. Dr. Heda Kvakan and Dr. Dominik N. MÃøller at the Experimental and Clinical Research Center at the Max DelbrÃøck Center do not intend Treg as a therapy. However, a better understanding of how the immune system fits into hypertension-induced organ damage could result from these studies (Circulation, Vol. 119, No. 22, June 9, 2009, 2904-2912 ).*
News of the day
Tummy Troubles -- Gastrin Key In Bacterial-Induced Stomach Cancer
Current research suggests that levels of gastrin play a key role in the development of Helicobacter-induced stomach cancer. The related report by Takaishi et al, "Gastrin is an essential cofactor for Helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice," appears in the July 2009 issue of The American Journal of Pathology.
Public Health

Harvard Researchers Say Insurers Put Profits Over Health

More than a decade after Harvard researchers first revealed that life and health insurance companies were major investors in tobacco stocks - prompting calls upon them to divest - the insurance industry has yet to kick the habit, they say. A new article on insurance company holdings, published in the New England Journal of Medicine, shows that U.S., Canadian and U.K.-based insurance firms hold at least $4.4 billion of investments in companies whose subsidiaries manufacture cigarettes, cigars, chewing tobacco and related products. Tobacco products currently contribute to the deaths of 5.4 million people worldwide annually, according to the World Health Organization. Tobacco use is a major risk factor for stroke, heart attack, lung disease and cancer. "Despite calls upon the insurance industry to get out of the tobacco business by physicians and others, insurers continue to put their profits above people"s health," said Dr. J. Wesley Boyd, the lead author of the article. "It"s clear their top priority is making money, not safeguarding people"s well-being." To illustrate their point, Boyd and his colleagues point to Newark, N.J.-based Prudential Financial Inc., which sells life insurance and long-term disability coverage. With total tobacco holdings of $264.3 million, Prudential Financial is a major investor in three tobacco firms, including Reynolds American, whose subsidiary R.J. Reynolds manufactures Camel and Pall Mall cigarettes, and Philip Morris, maker of the popular Marlboro brand. Sun Life Financial Inc., based in Toronto, sells life, health, disability and long-term care insurance. It also owns slightly over $1 billion in stock in two tobacco companies, including $890 million in Philip Morris. London-based Prudential Plc, which offers health, disability, and long-term care insurance, has holdings of $1.38 billion in two tobacco companies, including British American Tobacco, which markets Kent and Lucky Strike cigarettes. The researchers also itemize the substantial tobacco holdings of Northwestern Mutual of Milwaukee and Massachusetts Mutual Life of Springfield, Mass., along with those of Standard Life Plc, a health and life insurer based in Edinburgh, Scotland. Boyd and his co-authors, Drs. David Himmelstein and Steffie Woolhandler at the Cambridge Health Alliance and Harvard Medical School, culled their data from Osiris, a proprietary database of industrial, banking and insurance companies. Osiris draws upon Securities and Exchange Commission filings and news reports from providers like Dow Jones and Reuters. "Although investing in tobacco while selling life or health insurance may seem self-defeating," the authors write, "insurance firms have figured out ways to profit from both. Insurers exclude smokers from coverage or, more commonly, charge them higher premiums. Insurers profit - and smokers lose - twice over." The same researchers, all of whom are affiliated with Physicians for a National Health Program, first published data about the "tobacco-insurance company connection" in 1995 in the medical journal Lancet. They say that because private, for-profit insurers have repeatedly put their own financial gain over the public"s health, readers in the United States, Canada and the United Kingdom should be wary about insurance firms" participation in care. They add, "These data raise a red flag about the prospects of opening up vast new markets for private insurers at public expense, as has happened in our state of Massachusetts, whose recent health care reform is often cited as a model for national reform." Copies of the study are available at http://pnhp.org/tobacco/tobacco_article.pdf Reference: "Insurance industry investments in tobacco," J. Wesley Boyd, M.D., Ph.D.; David U. Himmelstein, M.D; Steffie Woolhandler, M.D., M.P.H. New England Journal of Medicine, June 4, 2009. Mark Almberg Physicians for a National Health Program


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):